Form 8-K Filing Summary for bioAffinity Technologies, Inc.

This Form 8-K details the results of the 2026 Annual Meeting of bioAffinity Technologies, Inc. Key outcomes include the approval of an amendment to the 2024 Equity Incentive Compensation Plan to increase the number of reserved shares to 1,000,000. Stockholders also elected six directors, ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm, and approved several proposals concerning warrant exercises and anti-dilution adjustments for Series B Preferred Stock and August 2025 Warrants. Additionally, the issuance of securities in non-public offerings and a potential change of control were approved, along with a reverse stock split proposal. The adjournment proposal was also approved, though not ultimately necessary due to the approval of other key proposals. The filing includes Exhibit 10.1, the First Amendment to the 2024 Equity Incentive Compensation Plan.